Home › Compare › ADAPY vs DGRO

ADAPY vs DGRO: Dividend Comparison 2026

ADAPY yields 17391.30% · DGRO yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ADAPY wins by $13116176655014998016.00M in total portfolio value
10 years
ADAPY
ADAPY
● Live price
17391.30%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$13116176655014998016.00M
Annual income
$12,969,477,336,575,606,000,000,000.00
Full ADAPY calculator →
DGRO
iShares Core Dividend Growth ETF
● Live price
2.13%
Share price
$68.98
Annual div
$1.47
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.6K
Annual income
$239.96
Full DGRO calculator →

Portfolio growth — ADAPY vs DGRO

📍 ADAPY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodADAPYDGRO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ADAPY + DGRO cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
ADAPY pays
DGRO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ADAPY
Annual income on $10K today (after 15% tax)
$1,478,260.87/yr
After 10yr DRIP, annual income (after tax)
$11,024,055,736,089,265,000,000,000.00/yr
DGRO
Annual income on $10K today (after 15% tax)
$181.24/yr
After 10yr DRIP, annual income (after tax)
$203.97/yr
At 15% tax rate, ADAPY beats the other by $11,024,055,736,089,265,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ADAPY + DGRO for your $10,000?

ADAPY: 50%DGRO: 50%
100% DGRO50/50100% ADAPY
Portfolio after 10yr
$6558088327507499008.00M
Annual income
$6,484,738,668,287,803,000,000,000.00/yr
Blended yield
98.88%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADAPY right now

ADAPY
Analyst Ratings
9
Buy
4
Hold
3
Sell
Consensus: Buy
Price Target
$2.83
+24508.7% upside vs current
Range: $1.00 — $4.00
Altman Z
-15.9
Piotroski
0/9
DGRO
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ADAPY buys
0
DGRO buys
0
No recent congressional trades found for ADAPY or DGRO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricADAPYDGRO
Forward yield17391.30% ✓2.13%
Annual dividend / share$2.00 ✓$1.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$13116176655014998016.00M ✓$31.6K
Annual income after 10y$12,969,477,336,575,606,000,000,000.00 ✓$239.96
Total dividends collected$13106484814212466688.00M ✓$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: ADAPY vs DGRO ($10,000, DRIP)

YearADAPY PortfolioADAPY Income/yrDGRO PortfolioDGRO Income/yrGap
1← crossover$1,749,830$1,739,130.43$11,293$213.22+$1.74M → ADAPY
2$286,281,979$284,409,660.27$12,730$217.32+$286.27M → ADAPY
3$43,793,237,807$43,486,916,089.97$14,326$221.10+$43793.22M → ADAPY
4$6,263,959,119,982$6,217,100,355,528.48$16,098$224.56+$6263959.10M → ADAPY
5$837,788,422,535,934$831,085,986,277,552.80$18,064$227.74+$837788422.52M → ADAPY
6$104,780,184,325,077,740$103,883,750,712,964,290.00$20,246$230.65+$104780184325.06M → ADAPY
7$12,254,629,759,849,812,000$12,142,514,962,621,979,000.00$22,666$233.30+$12254629759849.79M → ADAPY
8$1,340,341,587,727,856,400,000$1,327,229,133,884,817,100,000.00$25,349$235.73+$1340341587727856.50M → ADAPY
9$137,102,166,765,785,570,000,000$135,668,001,266,916,780,000,000.00$28,325$237.94+$137102166765785568.00M → ADAPY
10$13,116,176,655,014,997,000,000,000$12,969,477,336,575,606,000,000,000.00$31,624$239.96+$13116176655014998016.00M → ADAPY

ADAPY vs DGRO: Complete Analysis 2026

ADAPY — Stock

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Full ADAPY Calculator →

DGRO — ETF

The iShares Core Dividend Growth ETF seeks to track the investment results of an index composed of U.S. equities with a history of consistently growing dividends.

Full DGRO Calculator →
📬

Get this ADAPY vs DGRO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ADAPY vs SCHDADAPY vs JEPIADAPY vs OADAPY vs KOADAPY vs MAINADAPY vs VIGADAPY vs NOBLADAPY vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.